KaliVir Immunotherapeutics, Inc.

11:15 AM - 11:30 AM (EDT), Thursday, June 8, 2023 ・ Session Room 103
KaliVir Immunotherapeutics is a private biotechnology company dedicated to developing systemically deliverable oncolytic virus immunotherapies for the treatment of cancer using the vaccinia virus. We have developed the Vaccinia Enhanced Template (VET), a novel oncolytic virus platform that greatly enhances the systemic delivery capabilities of oncolytic vaccinia. The VET platform employs multiple proprietary genetic modifications that are uniquely combined to generate potent oncolytic therapy candidates that are optimized for intravenous administration and therapeutic transgene expression within tumor. Our lead candidate, VET3-TGI, is currently undergoing preclinical development with plans to enter the clinic in 2024.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
VET3-TGI, an oncolytic vaccinia virus expressing a novel TGF-beta inhibitor and IL12
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Head of Business Development
KaliVir Immunotherapeutics, Inc.